InnoCare Pharma Limited (HKG:9969)

Market Cap	24.74B
Revenue (ttm)	1.31B
Net Income (ttm)	-300.49M
Shares Out	1.76B
EPS (ttm)	-0.18
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	12,433,062
Average Volume	14,077,172
Open	11.44
Previous Close	11.44
Day's Range	11.12 - 11.86
52-Week Range	4.31 - 12.18
Beta	0.99
RSI	67.36
Earnings Date	May 14, 2025

About InnoCare Pharma

InnoCare Pharma Limited, a biopharmaceutical company, engages in discovering, developing, and commercializing drugs for the treatment of cancer and autoimmune diseases in China. The company develops Orelabrutinib, an BTK inhibitor to treat patients with relapsed and/or refractory (r/r) chronic lymphocytic leukemia, r/r mantle cell lymphoma, r/r Waldenstrom’s macroglobulinemia, r/r marginal zone lymphoma, r/r diffuse large B-cell lymphoma (DLBCL)- MCD, r/r central nervous system lymphoma, combo w/MIL-62, systemic lupus erythematosus, immune thro...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2015
• Employees: 1,089
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 9969

Financial Performance

In 2024, InnoCare Pharma's revenue was 1.01 billion, an increase of 36.68% compared to the previous year's 738.54 million. Losses were -440.63 million, -30.20% less than in 2023.

Financial numbers in CNY